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ABSTRACT. Fetuin-A, a hepatic glycoprotein present in the circulation, is a potential inhibitor for
systemic calcification. The main aim of this study was to evaluate the association between fetuin-A
and other biochemical parameters as facilitator factors for developing atherosclerosis in hemodialysis
(HD) patients. This case–control study was conducted on 44 HD patients undergoing treatment in
2012. Parathormone (i-PTH) and fetuin levels were performed by the enzyme-linked immunosorbent
assay method, high-sensitivity C-reactive protein (hs-CRP) by chemiluminescence, low-density
lipoprotein by direct enzymatic, calcium and albumin by colorimetric and phosphorous by ultraviolet
(UV) methods. Chi-square was used for evaluating the association between variables and t-test was
used for comparing the mean of the quantitative variables for the two groups. SPSS-16 software was
used for data analysis and P-value less than 5% was considered as significant. Mean of serum fetuin
level was 23.25 ± 4.90 ng/mL in HD patients and 32.92 ± 5.21 in the control group. Median of hs-CRP
was 2.45 mg/dL in the patients and 1.00 mg/dL in the control group and i-PTH was 74.3 pg/mL in the
patients and 7.30 pg/mL in the control group. The calcium–phosphorous product was 46.77 ± 14.22
mg/dL in the patient and 31.73 ± 6.48 mg/dL in the control group. A reverse significant association
was found between fetuin-A and hs-CRP in this study. In this study, serum fetuin-A level in HD
patients was lower than controls. Therefore, a low level of fetuin-A seems to be associated with
atherosclerosis, inflammation and malnutrition.
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Introduction
Cardiovascular diseases are the most impor-
tant causes of mortality among dialysis pa-
tients, and the mortality rate among dialysis
patients is more than that of the general popu-
lation.1 Calcification is a pathologic process in
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the patients with end-stage renal disease
(ESRD) that results in a wide spectrum of
pathological processes.1 Atherosclerosis risk
factors in the normal population are well
known, but their role on uremic atherosclerosis
is less studied.
Other than dialysis, duration and age, there
are other known risk factors for calcification
including elevated levels of parathormone (i-
PTH) and serum C-reactive protein (CRP), dys-
lipidemia and hyper hemocysteinemia and re-
duction of serum albumin. Although hyper-
phosphatemia and increased calcium intake
accompanied by increasing calcium phosphate
product are important causes of calcification in
ESRD patients,2 recent findings reveal that
inflammation also contributes to the develop-
ment of calcification.3 Inflammation is a multi-
factorial process in ESRD, and it seems that it
is a resultant effect of common and uncommon
risk factors.3 CRP is an inflammatory marker
that increases in the patients with acute in-
flammatory events. Association of CRP and
cardiovascular events is very strong and re-
mains independent even after adjusting for
other risk factors.4,5 In numerous investiga-
tions, the association of calcification with mal-
nutrition, inflammation and atherosclerosis or
related serum parameters such as fibrinogen
elevation, CRP and hypoalbominemia have been
confirmed.6-8
However, the high risk for cardiovascular di-
seases in ESRD patients may be related not
only to increasing definitive risk factors but
also to the relative lack of vascular protective
factors. Fetuin-A, a hepatic glycoprotein pre-
sent in circulation, is a potential inhibitor for
systemic calcification that is found to decrease
during inflammation.9,10 Fetuin-A binds to cal-
cium phosphate with severe adherence and,
therefore, it acts as a buffer for serum calcium
phosphate.
Various studies recommend that a decrease of
the serum fetuin levels, which is observed in
dialysis patients, facilitates extensive vascular
calcifications, and these changes in vessel wall
may be associated with increasing cardiovas-
cular mortality. Other factors that seem to
decrease calcification include PTH and related
peptides.11 High levels of PTH in circulation
can lead to vascular calcification, but normal
amounts of PTH have no influence on it or
may inhibit it.
The main objective of this study was to eva-
luate the association, if any, between fetuin-A
as an inhibitor factor for vascular calcification,
atherosclerosis and biochemical parameters as
facilitating factors for developing atheroscle-
rosis in hemodialysis (HD) patients.
Subjects and Methods
In this case–control study, we randomly en-
rolled 44 patients on HD referred to our aca-
demic and treatment centers of the Gorgan
Fifth Azar Hospital. Forty-four age- and sex-
matched controls were selected among the
healthy general population with normal urea
and creatinine. People with active infections
(fever or any evidence of infections), known
malignancy, connective tissue disorders and
inflammatory diseases were excluded from the
study. Demographic information was extracted
from patients’ medical files. Before dialysis, 5
mL blood was obtained from the patients and,
after isolating serums, they were stored at -
70ºC in a freezer. The necessary biochemical
tests were performed and, finally, the acquired
information was statistically evaluated and
analyzed.
Analysis of regression (logistic) was used for
predicting an effect of increasing independent
variables on the dependent variables, chi-
square was used for evaluating an association
between qualitative variables and t-test was
used for comparing the mean of the quanti-
tative variables for the two groups. SPSS soft-
ware was used for data analysis and P-value
less than 5% was considered as significant.
Results
In this study, 44 HD patients and 44 controls
were evaluated and compared regarding serum
fetuin-A level, calcium, phosphorous, PTH,
CRP, albumin and LDL. Among the 44 HD
patients, there were 24 males and 20 females.
The mean age of the patients was 53.75 ±
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12.83 years, whereas the mean age of the
controls was 53.86 ± 12.28 years. In this study,
the mean of serum fetuin level was 23.25 ±
4.90 ng/mL in HD patients and 32.92 ± 5.21
ng/mL in the control group. The mean serum
albumin level was 4.07 ± 0.44 mg/dL in the
patients and 4.46 ± 0.54 mg/dL in the control
group. The mean serum LDL level was 82.4 ±
23.41 mg/dL and 96.87 ± 33.30 mg/dL in the
HD and control groups, respectively. The me-
dian for hs-CRP was 2.45 µg/mL in the pa-
tients and 1.00 µg/mL in the controls; for PTH,
the levels were 74.3 pg/mL in the patients and
7.30 pg/mL in the control group. The calcium–
phosphorous product was 46.77 ± 14.22
mg/dL in the patients and 31.73 ± 6.48 mg/dL
in the control group. The mean of dialysis
duration was 29 months. A reverse significant
association was found between fetuin A and
hs-CRP in this study.
In addition, a significant association was found
between fetuin A and albumin (P = 0.05).
However, no significant association was found
between fetuin with dialysis duration, PTH,
LDL and calcium–phosphorous product.
Mean of serum fetuin-A level, albumin and
LDL showed a statistically significant diffe-
rence in the patients and healthy controls (P
<0.001 for fetuin and albumin; P <0.02 for
LDL). In addition, there was a statistically sig-
nificant difference between serum phosphoric
level and calcium–phosphorous product in
both groups (P <0.001). However, there was
no significant difference between the serum
calcium levels in both groups (P = 0.18). Also,
there was no significant difference between the
two groups regarding age (P = 0.96).
For comparing the serum PTH level and hs-
CRP in both groups, the median value was
used because these parameters did not have a
normal distribution. The median was 2.45 mg/
dL for hs-CRP in the patients and 1.00 mg/dL
in the controls. Median of PTH was 74.30 pg/
mL in the patients and 7.30 pg/mL in the con-
trol group. Therefore, these differences between
the serum PTH levels in the case and control
groups had a statistically significant (P <0.001)
difference, whereas this difference was not
significant (P = 0.86) for the hs-CRP levels.
In this study, the mean serum PTH level was
lower than the desired amount in 25 patients
(56.8%), desired in five patients (11.4%) and
higher than desired in 14 patients (31.8%). The
calcium–phosphorous product was higher than
normal in ten (22.7%) patients and lower than
55 in 43 (77.3%) patients. This product was
lower than 55 in all the controls. Therefore, the
calcium–phosphorous product showed a statis-
tically significant difference between the case
and control groups (P = 0.01, correlation co-
efficient = 0.36). In this study, there was no
statistically significant association between
serum fetuin-A level with calcium, calcium–
phosphorous co-efficient and LDL in the
patients group. However, there was a statis-
tically significant relationship between serum
fetuin-A level and albumin in this group (P =
0.01, correlation co-efficient = 0.36). In our
investigation, there was a reverse and sta-
tistically significant difference between serum
fetuin-A level and hs-CRP in the patients (P =
0.004, correlation coefficient = -0.42), but there
was no statistically significant association bet-
ween fetuin-A and parathormone (P = 0.12)
and dialysis duration (P = 0.6) in this group. In
the control group, there was no statistically
significant association between serum fetuin-A
level with calcium (P = 1.00), calcium–phos-
phorous product (P = 0.89), LDL (P = 0.6) and
albumin (P = 0.8). In the present study, there
was a statistically significant association bet-
ween serum fetuin-A level and hs-CRP in the
control group (P = 0.05, correlation coefficient
= -0.29). However, no statistically significant
association was found between serum fetuin-A
level and PTH (P = 0.77). There was a statis-
tically reverse significant difference between
serum fetuin-A level and hs-CRP in the pa-
tients (P = 0.004).
Discussion
It is now known that the high risk for car-
diovascular diseases in ESRD patients, in
addition to the conventional risk factors, may
be related to a relative lack of vascular protec-
tive factors. Fetuin-A, a hepatic glycoprotein
present in circulation, is a potential inhibitor
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for systemic calcification and is found to
decrease during inflammation.9,10 Fetuin-A
binds to calcium phosphate with severe adhe-
rence and, therefore, acts as a buffer for serum
calcium phosphate and potentially can prevent
calcification. Our study evaluated the fetuin-A
levels with other parameters of calcification.
In the Kayser Caglar study conducted on 50
patients with chronic kidney disease in 2007, a
reverse association was observed between
serum fetuin-A concentration and hs-CRP.12 In
our study also there was a statistically reverse
significant difference between serum fetuin-A
level and hs-CRP in the patients (P = 0.004).
Angela Yee Moon Wang et al in a study on
238 HD patients in 2005 showed an important
association between serum fetuin-A and
MIAC syndrome (malnutrition, inflammation,
atherosclerosis and valvular calcification) in
the patients. In addition, a strong relationship
was observed between IL-6 and CRP with
fetuin-A in this study.13 In 2005, Peter
Stenvinkel and colleagues in a cohort study on
258 ESRD patients found an important reverse
association between fetuin-A, CRP and IL-6.14
Ketteler et al15 performed a study on 312 HD
patients for evaluating calcification and cardio-
vascular disorders. They reported a reverse
association between serum fetuin-A and CRP
in these patients. Their results are completely
in agreement with the recent Wang study.13 In
the Osamu Oikawa study in 2007 on 40 HD
patients and 20 controls, it has been shown
that the mean of serum fetuin-A in the HD
patients had a negative association with hs-
CRP. In addition, in this study, the fetuin-A
concentration in HD patients was significantly
lower than that in controls.16 In the Jung et al
investigation in 2008 on 222 HD patients, the
authors showed that serum fetuin-A has a ne-
gative association with inflammatory markers
in circulation.17 In the Osamu Oikawa study, it
was observed that there was a positive asso-
ciation between mean of serum fetuin-A level
in HD patients with serum albumin.16 In our
study also there was a statistically significant
association between serum fetuin-A level and
albumin in the patients group (P = 0.01).
In the previous study of Wang, it has been
shown that fetuin-A is well compatible with
age-related CRP changes; also, the amounts of
this acute phase protein do not have any asso-
ciation with dialysis duration.18 In addition, in
the prospective part of this study, it has been
shown that treatment with dialysis is related to
a mild but important decrease in serum fetuin-
A levels. Ketteler and colleagues reported a
higher degree of coronary calcification in the
patients with long-term dialysis in comparison
with short-term dialysis.15 Furthermore, in the
Osamu Oikawa study, it has been shown that
the mean of serum fetuin-A in the HD patients
group has a negative association with dialysis
duration.16 In our study, similar to Wang’s
study, there was no statistically significant
association between fetuin-A and dialysis du-
ration (P = 0.6).
In the Osamu Oikawa study, it was observed
that serum fetuin-A levels in HD patients were
significantly lower than that in the controls.16
In our study also, the means of serum fetuin-A,
albumin and LDL were significantly different
in the patients and healthy control groups (P
<0.001 for fetuin and albumin, P <0.02 for
LDL).
Again in the Osamu Oikawa study, no im-
portant association was found between fetuin-
A concentration and biochemical parameters
such as Ca, P, iPTH and Ca–P product.16 In
our study, there was no statistically significant
association between fetuin-A and PTH (P =
0.12), but there was a statistically significant
difference between serum phosphorous levels
and calcium–phosphorous product in both
groups (P <0.001).
In this study, the serum fetuin-A level in HD
patients was lower than that in controls. Treat-
ment with dialysis was related to a mild but
important decrease in the serum fetuin level.
The fetuin-A levels in the patients showed a
positive association with serum albumin and a
reverse association with hs-CRP. Fetuin-A, via
its anti-inflammatory and calcification inhi-
bition capacities, may play a regulatory role in
atherosclerosis. An inflammatory reaction is
the major cause of low fetuin level in the
patients with malnutrition. Therefore, it is pur-
posed that a low level of fetuin-A is associated
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with atherosclerosis, inflammation and malnu-
trition. It seems that attempt on treatments for
increasing fetuin-A and eliminating malnu-
trition in the patients will be helpful in pre-
venting calcification among patients on HD.
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